ARS Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ARS Pharmaceuticals
SPRY Stock   10.57  0.13  1.25%   
ARS Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ARS Pharmaceuticals' valuation are provided below:
Gross Profit
114.9 M
Profit Margin
(0.56)
Market Capitalization
1 B
Enterprise Value Revenue
5.8908
Revenue
142.8 M
We have found one hundred twenty available fundamental signals for ARS Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of ARS Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself next year. Market Cap is likely to drop to about 810.8 M in 2026. Enterprise Value is likely to drop to about 723.5 M in 2026

ARS Pharmaceuticals Total Revenue

107.65 Million

Check ARS Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ARS Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 67.5 K, Gross Profit of 82.8 M or Other Operating Expenses of 111.4 M, as well as many indicators such as Price To Sales Ratio of 9.81, Dividend Yield of 0.0 or PTB Ratio of 3.76. ARS financial statements analysis is a perfect complement when working with ARS Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ARS Stock
Check out the analysis of ARS Pharmaceuticals Correlation against competitors.
For more information on how to buy ARS Stock please use our How to Invest in ARS Pharmaceuticals guide.

ARS Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets424 M403.8 M120.3 M
Slightly volatile
Short and Long Term Debt Total35.9 K37.8 K6.2 M
Slightly volatile
Other Current Liabilities15.7 M14.9 M3.6 M
Slightly volatile
Total Current Liabilities28.3 M27 M9.8 M
Slightly volatile
Property Plant And Equipment Net1.6 M959.4 K3.8 M
Slightly volatile
Accounts Payable11.9 M11.4 M2.9 M
Slightly volatile
Cash70.2 M58.4 M43.4 M
Slightly volatile
Non Current Assets Total20.4 M19.4 M7.6 M
Slightly volatile
Cash And Short Term Investments379.2 M361.1 M107.8 M
Slightly volatile
Common Stock Shares Outstanding123.6 M117.7 M51.4 M
Slightly volatile
Liabilities And Stockholders Equity424 M403.8 M120.3 M
Slightly volatile
Non Current Liabilities Total85.6 M81.6 M23.5 M
Slightly volatile
Other Current Assets7.1 M6.8 M2 M
Slightly volatile
Other Stockholder Equity458.7 M436.9 M120.8 M
Slightly volatile
Total Liabilities113.9 M108.5 M33.3 M
Slightly volatile
Total Current Assets403.7 M384.4 M112.7 M
Slightly volatile
Short Term Debt35.9 K37.8 K3 M
Slightly volatile
Other Liabilities2.5 M2.6 M3.3 M
Slightly volatile
Current Deferred Revenue931 K501.3 K2.5 M
Slightly volatile
Non Currrent Assets Other9.8 M9.3 M1.8 M
Slightly volatile
Other Assets3.6 M3.4 M935.8 K
Slightly volatile
Long Term Debt5 M4.4 M6.5 M
Slightly volatile
Net Receivables11.1 M10.5 M2.2 M
Slightly volatile
Property Plant And Equipment Gross829.6 K1.5 M374.5 K
Slightly volatile
Short and Long Term Debt3.3 M4 M2.9 M
Slightly volatile
Capital Stock8.6 K9 K162.2 K
Slightly volatile
Non Current Liabilities Other83.8 M79.8 M18.2 M
Slightly volatile
Net Working Capital194.3 M357.5 M95.1 M
Slightly volatile
Common Stock8.6 K9 K147.2 K
Slightly volatile
Property Plant Equipment383.2 K378.4 K158.5 K
Slightly volatile
Common Stock Total Equity7.2 K8.1 K8.8 K
Slightly volatile
Capital Surpluse279.5 M314.5 M343.2 M
Slightly volatile
Intangible Assets4.6 M8.8 M1.7 M
Slightly volatile

ARS Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization67.5 K71.1 K891.4 K
Slightly volatile
Other Operating Expenses111.4 M106.1 M38 M
Slightly volatile
Research Development20.3 M22.5 M17.1 M
Slightly volatile
Cost Of Revenue24.8 M23.6 M5.8 M
Slightly volatile
Total Operating Expenses86.5 M82.4 M32.3 M
Slightly volatile
Interest Expense1 M959.1 K287.8 K
Slightly volatile
Selling General Administrative86.5 M82.4 M21 M
Slightly volatile
Total Revenue107.6 M102.5 M29.6 M
Slightly volatile
Selling And Marketing Expenses109.2 K65.7 K171.8 K
Slightly volatile
Non Operating Income Net Other667.2 K750.6 K819.3 K
Slightly volatile

ARS Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow65.2 M81.6 M41.5 M
Slightly volatile
Capital Expenditures280.5 K506.7 K402 K
Pretty Stable
Total Cash From Financing Activities56 M83.3 M38.3 M
Slightly volatile
End Period Cash Flow70.2 M58.4 M43.4 M
Slightly volatile
Stock Based Compensation17.5 M16.7 M6.2 M
Slightly volatile
Change To Netincome5 M8.1 M4.6 M
Slightly volatile
Sale Purchase Of Stock456 K513 K559.9 K
Slightly volatile
Cash And Cash Equivalents Changes120.4 M135.4 M147.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.8110.321.1 K
Pretty Stable
Days Sales Outstanding32.0733.761.1 K
Slightly volatile
Stock Based Compensation To Revenue0.140.1518.5545
Pretty Stable
EV To Sales9.329.81951
Pretty Stable
Inventory Turnover3.153.553.8743
Slightly volatile
Days Of Inventory On Hand74.0383.2990.9086
Slightly volatile
Payables Turnover2.561.872.31
Pretty Stable
Sales General And Administrative To Revenue1.5 K1.4 K358
Slightly volatile
Research And Ddevelopement To Revenue0.190.241.3216
Pretty Stable
Capex To Revenue0.00540.00570.3869
Pretty Stable
Cash Per Share1.852.921.5206
Slightly volatile
Days Payables Outstanding150158385
Pretty Stable
Intangibles To Total Assets0.01750.01970.0215
Slightly volatile
Current Ratio20.2712.8414.2825
Slightly volatile
Receivables Turnover20.6111.1932.5025
Slightly volatile
Graham Number1.782.02.1791
Slightly volatile
Capex Per Share0.0090.00670.0107
Slightly volatile
Revenue Per Share0.870.830.4998
Pretty Stable
Interest Debt Per Share5.0E-45.0E-40.1882
Slightly volatile
Debt To Assets1.0E-41.0E-40.2385
Slightly volatile
Operating Cycle1111171.2 K
Slightly volatile
Days Of Payables Outstanding150158385
Pretty Stable
Effective Tax Rate0.02780.03130.0341
Slightly volatile
Quick Ratio20.2512.6414.2564
Slightly volatile
Net Income Per E B T0.780.870.9487
Slightly volatile
Cash Ratio1.851.957.0866
Slightly volatile
Days Of Inventory Outstanding74.0383.2990.9086
Slightly volatile
Days Of Sales Outstanding32.0733.761.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.11.0178
Very volatile
Fixed Asset Turnover19196.17524
Slightly volatile
Debt Ratio1.0E-41.0E-40.2385
Slightly volatile
Price Sales Ratio9.8110.321.1 K
Pretty Stable
Asset Turnover0.220.290.4875
Slightly volatile
Gross Profit Margin0.520.690.4001
Slightly volatile

ARS Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap810.8 M1.2 B1.3 B
Slightly volatile
Enterprise Value723.5 M1.1 B1.2 B
Slightly volatile

ARS Fundamental Market Drivers

ARS Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ARS Pharmaceuticals Financial Statements

ARS Pharmaceuticals investors use historical fundamental indicators, such as ARS Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in ARS Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue501.3 K931 K
Cost Of Revenue23.6 M24.8 M
Total Revenue102.5 M107.6 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue1.4 K1.5 K
Research And Ddevelopement To Revenue 0.20  0.19 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.83  0.87 
Ebit Per Revenue(0.04)(0.04)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GMGeneral Motors
GMGeneral Motors
CCitigroup

Additional Tools for ARS Stock Analysis

When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY